Cytokinetics to Report Q3 Results on November 6, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) has announced it will release its third-quarter financial results on November 6, 2024, at 4:00 PM ET. Following the release, a conference call led by the senior management will occur at 4:30 PM ET to review the company’s operational and financial performance, as well as future outlook.

The conference call will be webcast live and can be accessed through the Investors & Media section of Cytokinetics’ website. Participants can also listen to the call via telephone after registering in advance. Upon registration, they will receive a dial-in number and a unique passcode. The webcast will be archived on the company’s website for six months.

Cytokinetics is a specialty biopharmaceutical company in the late stages of development, focusing on cardiovascular conditions. They are at the forefront of muscle biology research, aiming to develop and commercialize treatments that enhance muscle function. The company is developing small molecule drug candidates that influence myocardial muscle function and contractility.

One of the key developments for Cytokinetics is the advancement of aficamten, a cardiac myosin inhibitor targeting obstructive hypertrophic cardiomyopathy (HCM). Following promising results from the Phase 3 clinical trial SEQUOIA-HCM, Cytokinetics has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration. They are also making regulatory submissions for aficamten in Europe for obstructive HCM treatment. 

Currently, aficamten is under evaluation in several clinical trials: MAPLE-HCM, which compares aficamten as monotherapy to metoprolol in patients with obstructive HCM; ACACIA-HCM, a Phase 3 trial investigating aficamten in patients with non-obstructive HCM; CEDAR-HCM, a trial focusing on a pediatric population with obstructive HCM; and FOREST-HCM, an open-label extension study for HCM patients.

In addition to aficamten, Cytokinetics is working on omecamtiv mecarbil, a cardiac muscle activator targeting heart failure patients. Furthermore, they are developing CK-586, another cardiac myosin inhibitor with a different mechanism from aficamten, aimed at treating heart failure with preserved ejection fraction (HFpEF).

Cytokinetics continues to pioneer in muscle biology and cardiovascular treatments, working towards innovative solutions for severe diseases where cardiac muscle performance is impaired. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!